{
    "title": "111_hr6331",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Generating Antibiotic Incentives Now \nAct of 2010''.\n\nSEC. 2. TABLE OF CONTENTS.\n\n    The table of contents of this Act is as follows:\n\nSec. 1. Short title.\nSec. 2. Table of contents.\nSec. 3. Extension of exclusivity period.\nSec. 4. Priority review.\nSec. 5. Fast track product.\nSec. 6. Clinical trials.\n\nSEC. 3. EXTENSION OF EXCLUSIVITY PERIOD.\n\n    (a) In General.--The Federal Food, Drug, and Cosmetic Act is \namended by inserting after section 505D (21 U.S.C. 355e) the following:\n\n``SEC. 505E. EXTENSION OF EXCLUSIVITY PERIOD FOR NEW QUALIFIED \n              INFECTIOUS DISEASE PRODUCTS.\n\n    ``(a) Extension.--If, prior to approval or licensure of a drug or \nbiological product pursuant to an application that is submitted under \nsection 505(b) of this Act or section 351(a) of the Public Health \nService Act, the Secretary determines that the drug or biological \nproduct is a qualified infectious disease product, then the exclusivity \nperiod for such qualified infectious disease product is deemed to be \nextended by 5 years.\n    ``(b) Limited to First Licensure.--Subsection (a) does not apply to \nthe approval or licensure of--\n            ``(1) a supplement for the qualified infectious disease \n        product; or\n            ``(2) a subsequent application filed by the same sponsor or \n        manufacturer of the qualified infectious disease product (or a \n        licensor, predecessor in interest, or other related entity) \n        for--\n                    ``(A) a change (not including a modification to the \n                structure of the qualified infectious disease product) \n                that results in a new indication, route of \n                administration, dosing schedule, dosage form, delivery \n                system, delivery device, or strength; or\n                    ``(B) a modification to the structure of the \n                qualified infectious disease product that does not \n                result in a change in--\n                            ``(i) safety or effectiveness in the case \n                        of a drug; or\n                            ``(ii) safety, purity, or potency in the \n                        case of a biological product.\n    ``(c) Determination.--At the request of any person submitting an \napplication described in subsection (a), the Secretary shall, not later \nthan 30 days after the submission of such request and prior to approval \nof the application, determine whether the drug or biological product is \na qualified infectious disease product.\n    ``(d) Regulations.--The Secretary shall promulgate regulations for \ncarrying out this section. The Secretary shall promulgate the initial \nregulations for carrying out this section not later than 12 months \nafter such date of enactment.\n    ``(e) Definitions.--In this section:\n            ``(1) Exclusivity period.--The term `exclusivity period' \n        means, with respect to a qualified infectious disease product \n        approved or licensed under section 505 of this Act or section \n        351 of the Public Health Service Act, the period of time (as \n        extended under section 505A or 527 of this Act or section \n        351(m) of the Public Health Service Act) during which such \n        section 505 or 351 prohibit the Secretary from making effective \n        the approval of another application under such section 505 or \n        351 for such product for a person who is not the holder of such \n        approved application or of such approved license.\n            ``(2) Qualified infectious disease product.--The term \n        `qualified infectious disease product' means an antibiotic \n        drug, or a diagnostic test including a point-of-care diagnostic \n        test, for treating, detecting, preventing, or identifying a \n        qualifying pathogen.\n            ``(3) Qualifying pathogen.--The term `qualifying pathogen' \n        means--\n                    ``(A) resistant gram positive pathogens, including \n                methicillin-resistant Staphylococcus aureus (MRSA), \n                vancomycin-resistant Staphylococcus aureus (VRSA), and \n                vancomycin-resistant enterococcus (VRE);\n                    ``(B) multi-drug resistant gram negative bacteria, \n                including Acinetobacter, Klebsiella, Pseudomonas, and \n                E. coli species;\n                    ``(C) multi-drug resistant tuberculosis; or\n                    ``(D) any other infectious pathogen identified for \n                purposes of this section by the Secretary, in \n                concurrence with infectious disease clinicians and \n                appropriate professional associations, as a significant \n                threat to public health because of drug resistance or \n                other factors (or likely to become such a threat).''.\n    (b) Application.--Section 505E of the Federal Food, Drug, and \nCosmetic Act, as added by subsection (a), shall apply with respect to \nany drug or biological product that is first approved or licensed under \nsection 505 of such Act (21 U.S.C. 355) or section 351 of the Public \nHealth Service Act (42 U.S.C. 262) on or after the date of the \nenactment of this Act.\n\nSEC. 4. PRIORITY REVIEW.\n\n    (a) Amendment.--Chapter V of the Federal Food, Drug, and Cosmetic \nAct is amended by inserting after section 524 (21 U.S.C. 360n) the \nfollowing:\n\n``SEC. 524A. PRIORITY REVIEW FOR QUALIFIED INFECTIOUS DISEASE PRODUCTS.\n\n    ``(a) In General.--If the Secretary determines under section 505E \nthat a drug is a qualified infectious disease product, the Secretary \nshall give priority review to the application for approval or licensure \nof such product submitted under section 505(b) of this Act or section \n351(a) of the Public Health Service Act.\n    ``(b) Definition.--In this section, the term `priority review', \nwith respect to an application described in subsection (b), means \nreview and action by the Secretary on such application not later than 6 \nmonths after receipt by the Secretary of such application.''.\n    (b) Application.--Section 524A of the Federal Food, Drug, and \nCosmetic Act, as added by subsection (a), shall apply with respect to \nan application that is submitted under section 505(b) of such Act (21 \nU.S.C. 355(b)) or section 351(a) of the Public Health Service Act (42 \nU.S.C. 262(a)) on or after the date of the enactment of this Act.\n\nSEC. 5. FAST TRACK PRODUCT.\n\n    Paragraph (1) of section 506(a) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 356(a)) is amended by inserting after ``if it \nis intended for the treatment of a serious or life-threatening \ncondition and it demonstrates the potential to address unmet medical \nneeds for such a condition'' the following: ``or if the Secretary \ndetermines under section 505E that the drug is a qualified infectious \ndisease product''.\n\nSEC. 6. CLINICAL TRIALS.\n\n    (a) Review and Revision of Guidelines.--\n            (1) In general.--Not later than 1 year after the date of \n        the enactment of this Act, and not later than 4 years \n        thereafter, the Secretary shall--\n                    (A) review the guidelines of the Food and Drug \n                Administration for the conduct of clinical trials with \n                respect to antibiotic drugs; and\n                    (B) as appropriate, revise such guidelines to \n                reflect developments in scientific and medical \n                information and technology and to ensure clarity \n                regarding the procedures and requirements for approval \n                of an antibiotic drug under chapter V of the Federal \n                Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) or \n                section 351 of the Public Health Service Act (42 U.S.C. \n                262).\n            (2) Issues for review.--At a minimum, the review under \n        paragraph (1) shall address the appropriate animal models of \n        infection, in vitro techniques, valid micro-biological \n        surrogate markers, the use of non-inferiority versus \n        superiority trials, and appropriate delta values for non-\n        inferiority trials.\n            (3) Reports to congress.--Not later than 1 year after the \n        date of the enactment of this Act, and annually thereafter for \n        the next 4 years, the Secretary shall submit a report to the \n        Congress on the progress of the review under paragraph (1).\n            (4) Rule of construction.--Except to the extent to which \n        the Secretary of Health and Human Services makes revisions \n        under paragraph (1)(B), nothing in this section shall be \n        construed to repeal or otherwise affect the guidelines of the \n        Food and Drug Administration.\n    (b) Recommendations for Investigations.--\n            (1) Request.--The sponsor of a drug intended to be used to \n        treat, detect, prevent, or identify a qualifying pathogen may \n        request that the Secretary provide written recommendations for \n        nonclinical and clinical investigations which may be conducted \n        with the drug before--\n                    (A) it may be approved for such use under section \n                505 of the Federal Food, Drug, and Cosmetic Act (21 \n                U.S.C. 355); or\n                    (B) if the drug is a biological product, it may be \n                licensed for such use under section 351 of the Public \n                Health Service Act.\n            (2) Recommendations.--If the Secretary has reason to \n        believe that a drug for which a request is made under this \n        subsection is a qualified infectious disease product, the \n        Secretary shall provide the person making the request written \n        recommendations for the nonclinical and clinical investigations \n        which the Secretary believes, on the basis of information \n        available to the Secretary at the time of the request, would be \n        necessary for--\n                    (A) approval under section 505 of the Federal Food, \n                Drug, and Cosmetic Act (21 U.S.C. 355) of such drug for \n                the use described in paragraph (1); or\n                    (B) licensing under section 351 of the Public \n                Health Service Act (42 U.S.C. 262) of such drug for \n                such use.\n    (c) Definitions.--In this section:\n            (1) The term ``biological product'' has the meaning given \n        to such term in section 351 of the Public Health Service Act \n        (42 U.S.C. 262).\n            (2) The term ``drug'' has the meaning given to such term in \n        section 201 of the Federal Food, Drug, and Cosmetic Act (21 \n        U.S.C. 321).\n            (3) The term ``qualifying pathogen'' has the meaning given \n        such term in section 505E of the Federal Food, Drug, and \n        Cosmetic Act, as added by section 3.\n            (4) The term ``Secretary'' means the Secretary of Health \n        and Human Services, acting through the Commissioner of Food and \n        Drugs."
}